20 Rec 4 FEFFE 2 3 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

To be determined

Appl. No.: (U.S. National Phase of

PCT/HU2004/000026); U.S. Appl. No. (to be assigned); I.A. Filing Date: March 23, 2004

Filed: (Herewith)

For: Process for the Synthesis of

Amorphous Atorvastatin Calcium

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2124.0070000/HLK/SEP

Preliminary Amendment Under 37 C.F.R. § 1.115

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying However, if additional extensions of time are necessary to prevent this paper.

under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.